| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/30/2002 | WO2002041763A2 Compositions and methods for the therapy and diagnosis of colon cancer |
| 05/30/2002 | WO2002028440B1 Methods and compositions for modulating t cell activation and uses thereof |
| 05/30/2002 | WO2002024864A3 Antisense modulation of syntaxin 4 interacting protein expression |
| 05/30/2002 | WO2002022782A3 Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
| 05/30/2002 | WO2002022679A3 Variants of phleum pratense allergenic proteins |
| 05/30/2002 | WO2002020736A9 Proteases |
| 05/30/2002 | WO2002018581A9 G-protein coupled receptors |
| 05/30/2002 | WO2002018441A3 Electroprocessed fibrin-based matrices and tissues |
| 05/30/2002 | WO2002018438A9 Modified proteins, isolated novel peptides, and uses thereof |
| 05/30/2002 | WO2002015919A3 Saratin for inhibiting platelet adhesion to collagen |
| 05/30/2002 | WO2002014345A3 Antimicrobial peptides isolated from mast cells |
| 05/30/2002 | WO2002013844A3 Specific autoimmune reactions against isomerised/optically inverted epitopes: application for treatment of autoimmune diseases |
| 05/30/2002 | WO2002012328A8 Compositions and methods for the therapy and diagnosis of colon cancer |
| 05/30/2002 | WO2002011785A3 Manipulation of arterial-venous identity |
| 05/30/2002 | WO2002006477A9 A novel polypeptide-homo topoisomerase 12.1 and polynucleotide encoding said polypeptide |
| 05/30/2002 | WO2002005792A3 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 05/30/2002 | WO2002002756A3 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis |
| 05/30/2002 | WO2002000723A3 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 05/30/2002 | WO2002000254A3 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 05/30/2002 | WO2001098482A3 Liver-specific gene expression cassettes, and methods of use |
| 05/30/2002 | WO2001097841A3 Qs-21 and il-12 as an adjuvant combination |
| 05/30/2002 | WO2001096364A3 Peptides that stimulate cell survival and axon regeneration |
| 05/30/2002 | WO2001095928A3 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 05/30/2002 | WO2001094412A3 56201, a novel human sodium ion channel family member and uses thereof |
| 05/30/2002 | WO2001092580A3 Lyophilizable and enhanced compacted nucleic acids |
| 05/30/2002 | WO2001092333A3 Use of adnf for enhancing learning and memory |
| 05/30/2002 | WO2001092296A3 Regulation of human isotocin-like g protein-coupled receptor |
| 05/30/2002 | WO2001091789A3 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 05/30/2002 | WO2001087979A3 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| 05/30/2002 | WO2001087978A3 Human abc transporter and its use |
| 05/30/2002 | WO2001087934A3 Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides |
| 05/30/2002 | WO2001087929A3 Regulation of human dopamine-like g protein-coupled receptor |
| 05/30/2002 | WO2001087330A3 Compositions and methods for achieving immune suppression |
| 05/30/2002 | WO2001085931A3 Polypeptide inhibiting a proton-gated na+ channel |
| 05/30/2002 | WO2001083520A3 Polyacid glycopeptide derivatives |
| 05/30/2002 | WO2001078700A3 Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine |
| 05/30/2002 | WO2001078683A3 Sustained release formulations comprising growth hormone |
| 05/30/2002 | WO2001075119A3 21509 and 33770, novel human dehydrogenase family members and uses thereof |
| 05/30/2002 | WO2001074858A3 Methods for altering t cell activation |
| 05/30/2002 | WO2001074431A3 Dispensing devices and liquid formulations |
| 05/30/2002 | WO2001074390A3 The use of a calcium channel blocker for treating renal disorders |
| 05/30/2002 | WO2001068702A3 Regulation of human g protein-coupled receptor |
| 05/30/2002 | WO2001068679A3 Peptides targeting specifically tumor-derived endothelial cells |
| 05/30/2002 | WO2001066776A3 Novel l-form bacterial strains, method for producing same and the use thereof for producing gene products |
| 05/30/2002 | WO2001066746A3 G-protein coupled receptor related polypeptides |
| 05/30/2002 | WO2001064877A3 Human schizophrenia gene |
| 05/30/2002 | WO2001062296A3 Non-aqueous injectable formulations for extended release of somatotropin |
| 05/30/2002 | WO2001053456A3 Methods and materials relating to prothrombinase-like polypeptides and polynucleotides |
| 05/30/2002 | WO2001049847A3 26904, 38911, and 39404, seven-transmembrane proteins/g-protein coupled receptors |
| 05/30/2002 | WO2001046243A3 A new polypeptide-ring finger protein 8 and the polynucleotide encoding it |
| 05/30/2002 | WO2001045731A9 Particulate drug-containing products and method of manufacture |
| 05/30/2002 | WO2001043759A3 Use of 11cby popypeptides and polynuceotides |
| 05/30/2002 | WO2001042282A9 Depsipeptide and congeners thereof for use as immunosuppressants |
| 05/30/2002 | WO2001041741A9 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 05/30/2002 | WO2001040264A9 Peptide antigens |
| 05/30/2002 | WO2001039799A9 Passive desensitization |
| 05/30/2002 | WO2001039600A9 Use of hsp27 as an anti-inflammatory agent |
| 05/30/2002 | WO2001029063A8 Death domain-containing receptor polynucleotides, polypeptides, and antibodies |
| 05/30/2002 | WO2001021795A9 Fatty acid transport proteins |
| 05/30/2002 | WO2001020037A3 Peroxisome proliferator-activated receptor alpha and disorders of lipid metabolism |
| 05/30/2002 | WO2001016300A3 Method of identifying inhibitors of cdc25 |
| 05/30/2002 | WO2000078952A8 Human rna metabolism proteins (rmep) |
| 05/30/2002 | WO2000052205A8 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 05/30/2002 | WO2000051567A8 Processes for making pharmaceutical oral ecb formulations and compositions |
| 05/30/2002 | WO2000051564A8 Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| 05/30/2002 | US20020065416 Anti-inflammatory agents |
| 05/30/2002 | US20020065406 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of hematopoietic defects |
| 05/30/2002 | US20020065399 Aerosolized polypeptide for use in treatment of lung disorders lungs |
| 05/30/2002 | US20020065398 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (egf-r); diagnostic and therapeutic use |
| 05/30/2002 | US20020065397 Protecting therapeutic compositions from host-mediated inactivation |
| 05/30/2002 | US20020065395 Polypeptide for use as diagnostic tool in screening bactericides |
| 05/30/2002 | US20020065394 Nucleotide sequences for use in human diagnostics and therapeutics |
| 05/30/2002 | US20020065393 Human hypoxanthine- (guanine) phosphoribosy1 transferase-2 |
| 05/30/2002 | US20020065391 Compound for use in the treatment of arthritis, inflammatory bowel disease, nervous system and cardiovascular disorders, arteriosclerosis, restenoses, diabetes, grafted organ damage, asthma, allergies, tumor metastasis and malaria |
| 05/30/2002 | US20020065324 Methods of inducing ovulation |
| 05/30/2002 | US20020065286 Treating chronic venous ulcers, arterial ulcers, chronic decubitus, acute wounds with a cGMP PDE5 inhibitor, such as Sildenafil; improved blood supply to the wound region; also in combination with a matrix metalloprotease inhibitor and/or a urokinase type plasminogen activator inhibitor |
| 05/30/2002 | US20020065284 Dipeptide derivatives |
| 05/30/2002 | US20020065273 Hormone therapy methods and hormone products for abating coronary artery blockage |
| 05/30/2002 | US20020065264 Heterocylic leaving group containing -o-Het, or -s-Het, wherein Heterocyclic rings selected from pyridine, pyrole, furan, pyrimidine or proline derivatives |
| 05/30/2002 | US20020065255 Disodium salt of active delivery agents (drugs) form solvates with ethanol and hydrates with water; greater efficacy for delivering active agents than monosodium salt |
| 05/30/2002 | US20020065243 Controlled activation of DNA molecules for gene therapy using a heat- or light-inducible promoter; levels of gene expression modulated by antibiotic concentrations; side- effects reduction; breast/ovarian/prostate cancers; tumors |
| 05/30/2002 | US20020065241 A recombinant polynucleotide of first polynucleotides coding an antigenic peptide and are operatively linked to each other to enhance translation of the polynucleotides to the peptides and binding to MHC; cancer vaccine |
| 05/30/2002 | US20020065239 Antidiabetic agents; obesity and diabetic-related conditions; administration of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modififying proteins |
| 05/30/2002 | US20020065238 EPO primary response gene, EPRG3pt |
| 05/30/2002 | US20020065231 Method for producing biologically active products |
| 05/30/2002 | US20020065227 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 05/30/2002 | US20020065226 Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy |
| 05/30/2002 | US20020065225 Methods of determining altered NDPK functions and the diagnosis of cystic fibrosis |
| 05/30/2002 | US20020065223 Isolated nucleic acid molecules encoding C/SKARP)-1 (Cardiac/Skeletal Muscle-Restricted Ankyrin-Repeat Containing Protein); antisense nucleic acid molecules, recombinant expression vectors; cardiotonic agents; muscles disorders |
| 05/30/2002 | US20020065222 Method of stimulation hair growth |
| 05/30/2002 | US20020065221 Control of protein synthesis, and screening method for agents |
| 05/30/2002 | US20020065220 For use in diagnosis and therapy of disorders treating disorders related to these novel human immunoglobulin-like (Ig- like) proteins |
| 05/30/2002 | US20020065219 Water soluble thiazolyl peptide derivatives |
| 05/30/2002 | US20020065218 VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor |
| 05/30/2002 | US20020065217 Treatments which elevate functional glycosylated leptin transport factor, for controlling weight and obesity |
| 05/30/2002 | US20020065216 Novel method of diagnosing and treating gliomas |
| 05/30/2002 | US20020065215 Isolated P2Y-like receptor polypeptide, polynucleotides encoding the same and methods of screening compounds as modulators of P2Y receptors or their expression; purinergic receptors |
| 05/30/2002 | US20020065214 Method of treating congestive heart failure |
| 05/30/2002 | US20020065213 Increasing the duration of expression of a delivered gene in target cells by delivering a gene encoding a cellular retention activity and nuclear binding sequence to target cells before or during gene of interest delivery |
| 05/30/2002 | US20020065211 Increasing function of organs having reduced red blood cell flow |